Back to top
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
IN BRIEF: Medtronic says MiniMed insulin pump an economical option
Medtronic PLC - Dublin-based medical device company - Says that recent studies in the UK and Singapore of its MiniMed 780G system showed that the device serves as a cost-effective therapy option for people living with type 1 diabetes compared to standard care options. The MiniMed is an insulin pump system that automatically adjusts blood sugars every five minutes. The UK study demonstrated that the device in healthcare settings in Europe saved on average EUR32,000 in long-term complications avoided per person, as well as improved quality-adjusted life expectancy for diabetes patients. Similar results were found in Asia, Medtronic says.
Current stock price: USD80.26, down 1.3% in New York on Wednesday
12-month change: down 11%
By Hugh Cameron, Alliance News reporter
Comments and questions to newsroom@alliancenews.com
Copyright 2024, Alliance News